Cialis and Diphenhydramine Interaction: What You Need to Know

What Is the Interaction Between Tadalafil and Diphenhydramine?

The combination produces two overlapping pharmacodynamic effects: additive central nervous system depression and opposing actions on smooth muscle tone in the bladder and urethra. Neither drug significantly alters the other's blood concentration at standard doses, so the risk is not about one drug raising the level of the other. The risk is about what both drugs do to the body at the same time.

Tadalafil: How It Works

Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor approved by the FDA for erectile dysfunction (ED), BPH, and pulmonary arterial hypertension [1]. It works by blocking the breakdown of cyclic guanosine monophosphate (cGMP), causing smooth muscle relaxation in the penile vasculature, prostate, bladder neck, and pulmonary arteries. This vasodilation lowers systemic vascular resistance and can reduce blood pressure by approximately 8/7 mmHg at the 10 mg dose, as documented in the FDA-approved prescribing information [1].

Tadalafil is metabolized hepatically by CYP3A4. Its half-life is approximately 17.5 hours, which is substantially longer than sildenafil (4 to 5 hours) or vardenafil (4 to 5 hours) [1]. That extended half-life means any interaction persists well beyond the dosing window.

Diphenhydramine: How It Works

Diphenhydramine is a first-generation H1-receptor antihistamine with three relevant pharmacological actions [2]:

• H1 receptor antagonism (antiallergic, antipruritic)
• Muscarinic receptor antagonism (anticholinergic)
• CNS histamine blockade (sedation)

The anticholinergic action inhibits detrusor muscle contraction in the bladder, which can impair urination. The CNS action depresses alertness, reaction time, and autonomic reflex speed. Both of these effects interact meaningfully with tadalafil's profile [2].

Diphenhydramine is metabolized primarily by CYP2D6 with minor CYP3A4 involvement [3]. At the standard 25 to 50 mg OTC dose, it does not meaningfully inhibit CYP3A4 and therefore does not raise tadalafil plasma concentrations to a clinically significant degree.

Pharmacokinetic Interaction: Why CYP3A4 Matters Here

Tadalafil's concentration is highly sensitive to strong CYP3A4 inhibitors. The FDA label states that ketoconazole 400 mg daily increased tadalafil AUC by 312% and C-max by 22% [1]. Ritonavir raised tadalafil AUC by 124% [1]. Diphenhydramine does not belong to that category.

A 2005 in-vitro analysis published in Drug Metabolism and Disposition confirmed that diphenhydramine's CYP3A4 inhibitory constant (Ki) is sufficiently high that clinically observed plasma concentrations do not produce meaningful enzyme inhibition [3]. This means a patient taking tadalafil 5 mg daily for BPH and then taking diphenhydramine 25 mg for seasonal allergies will not experience a pharmacokinetically driven spike in tadalafil levels.

CYP2D6 poor metabolizers accumulate higher diphenhydramine concentrations, which could amplify the drug's anticholinergic and sedative effects independently of tadalafil [4]. Genetic CYP2D6 status may matter more than is commonly recognized.

P-glycoprotein and Transporter Considerations

Tadalafil is not a clinically significant substrate or inhibitor of P-glycoprotein (P-gp) at therapeutic doses [1]. Diphenhydramine has some P-gp inhibitory activity, but at 25 to 50 mg oral doses the interaction is not expected to alter tadalafil CNS penetration in a clinically meaningful way [5]. Current evidence does not support a transporter-mediated interaction at standard OTC doses.

Pharmacodynamic Interaction: Where the Real Risk Lives

CNS Depression and Dizziness

Tadalafil causes vasodilation-related dizziness in approximately 2 to 3% of patients at the 10 mg dose according to phase III trial data [1]. Diphenhydramine causes sedation in approximately 10 to 42% of adults at 25 to 50 mg doses [6]. When both are present, the background risk of dizziness and unsteadiness is additive.

A 2016 analysis in the Journal of the American Geriatrics Society examined fall risk from anticholinergic medications and noted that diphenhydramine was among the agents most consistently associated with increased fall-related hospitalization in adults over 65 [7]. Falls in men already experiencing PDE5-inhibitor-related postural hypotension represent a compounded risk that deserves explicit counseling.

Anticholinergic Burden and Urinary Retention

Tadalafil 5 mg daily is FDA-approved for BPH and works partly by relaxing smooth muscle in the prostate and bladder neck, which improves urinary flow [1]. Diphenhydramine acts in the opposite direction: its muscarinic blockade inhibits detrusor contractility, tightens the bladder neck, and can precipitate acute urinary retention in susceptible men [8].

A 2008 study in BJU International (N=2,080) found that anticholinergic medications increased the relative risk of acute urinary retention by 1.8-fold in men with pre-existing lower urinary tract symptoms (LUTS) [8]. Men using tadalafil for BPH are, by definition, a LUTS population. Giving them diphenhydramine may partially or fully reverse the urinary benefit of tadalafil while adding its own retention risk.

Blood Pressure and Hemodynamic Overlap

Diphenhydramine can cause first-dose orthostatic hypotension, particularly in older patients [9]. Tadalafil independently lowers blood pressure. A 2002 randomized, placebo-controlled study in the American Journal of Cardiology (N=40) documented that tadalafil 10 mg produced a mean maximal decrease in systolic blood pressure of 8.3 mmHg compared with placebo [10]. When combined with diphenhydramine's vasodilatory and autonomic-blunting effects, the composite hypotensive pressure could be clinically relevant, especially on first exposure.

The American Heart Association's guidance on managing cardiovascular risk in men using PDE5 inhibitors identifies additive hypotension as a monitoring priority whenever other vasoactive agents are added [11].

Who Is at Highest Risk?

The table below outlines a clinical risk-stratification framework for providers assessing this combination in practice.

| Patient Profile | Key Risk | Recommended Action | |---|---|---| | Male <50, healthy, using tadalafil on-demand for ED | Low-moderate | Counsel on dizziness; limit diphenhydramine to 25 mg at night | | Male 50 to 64, tadalafil daily 5 mg for BPH | Moderate | Review urinary symptoms before and 48 hours after adding diphenhydramine | | Male 65+, tadalafil daily 5 mg for BPH, any antihypertensive | High | Avoid routine diphenhydramine; consider loratadine (non-sedating) instead | | Any patient on concomitant alpha-blockers | High | Combination is already cautioned by FDA label; adding anticholinergic worsens hypotension risk | | CYP2D6 poor metabolizer (known) | Moderate-high | Diphenhydramine will accumulate; sedative and anticholinergic effects amplified |

The Beers Criteria, published by the American Geriatrics Society and last updated in 2023, explicitly list diphenhydramine as a medication to avoid in adults aged 65 and older due to its anticholinergic potency and CNS effects [12]. Men in this age group using tadalafil for BPH are exactly the population that should seek an alternative antihistamine.

What the FDA Labels Say

Tadalafil Prescribing Information

The FDA-approved tadalafil label (NDA 021368) identifies the following interaction categories [1]:

• Strong CYP3A4 inhibitors: dose-limit tadalafil to 10 mg every 72 hours (or 2.5 mg daily if used for BPH/PAH)
• Alpha-blockers: initiate tadalafil at 2.5 mg daily; titrate cautiously
• Antihypertensives: expect additive blood pressure lowering
• Alcohol: additive hypotension documented at 0.7 g/kg ethanol

The label does not name diphenhydramine specifically, which reflects the absence of a PK interaction rather than a safety endorsement of the combination.

Diphenhydramine Labeling

The FDA's OTC monograph for diphenhydramine includes a standard warning: "May cause drowsiness; alcohol, sedatives, and tranquilizers may increase the drowsiness effect. Avoid alcoholic beverages while taking this product" [13]. The label does not reference PDE5 inhibitors. This is an OTC monograph limitation, not a pharmacological clearance. The class of cardiovascular agents that cause vasodilation and the sedative/anticholinergic properties of diphenhydramine warrant provider-level discussion regardless of the label's silence.

Monitoring and Clinical Management

When the Combination Cannot Be Avoided

Some patients genuinely need both medications temporarily, for example a man using daily tadalafil for BPH who develops an acute allergic reaction requiring antihistamine coverage. In those cases, the following steps reduce risk:

1. Use the lowest effective diphenhydramine dose, typically 25 mg rather than 50 mg.
2. Time the diphenhydramine dose for bedtime, when the patient is recumbent and the vasodilatory risk of postural hypotension is lower.
3. Measure sitting and standing blood pressure before and approximately 1 hour after the first combined dose if feasible.
4. Instruct the patient to rise slowly from bed or a chair for at least the first 24 hours.
5. Warn the patient explicitly not to drive or operate machinery.
6. Reassess urinary symptoms after 24 to 48 hours; if voiding becomes difficult, stop diphenhydramine immediately.

Safer Alternatives to Diphenhydramine

Second-generation, non-sedating antihistamines have substantially lower anticholinergic burden and do not carry the same CNS depression risk [14]. Options include:

• Loratadine 10 mg daily (Claritin): minimal anticholinergic activity, no meaningful CYP3A4 inhibition [14]
• Cetirizine 10 mg daily (Zyrtec): slightly more sedating than loratadine but far less than diphenhydramine [14]
• Fexofenadine 180 mg daily (Allegra): essentially no CNS penetration, no anticholinergic effect [14]

A 2014 systematic review in Allergy (N=8,776 across 17 trials) confirmed that second-generation antihistamines produce equivalent or superior symptom control for allergic rhinitis compared with first-generation agents, with a significantly lower sedation profile [15]. There is rarely a compelling clinical reason to choose diphenhydramine over these alternatives in a patient already taking tadalafil.

Special Populations

Older Adults

As noted above, the 2023 Beers Criteria explicitly warn against diphenhydramine in adults 65 and older [12]. Tadalafil 5 mg daily is commonly prescribed in this population for BPH. The overlap of these two patient groups is large. The American Geriatrics Society's direct quotation from the 2023 update is: "Diphenhydramine... Use should be avoided in older adults because of increased risks of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity" [12]. Providers should document the Beers Criteria consideration whenever this combination is considered in patients aged 65 or older.

Patients With Cardiovascular Disease

Men with stable cardiovascular disease who are already on nitrates cannot use tadalafil at all, per the FDA label [1]. Men on antihypertensives represent the more common scenario. For these patients, adding diphenhydramine's hemodynamic effects on top of the tadalafil-antihypertensive interaction is a three-way compounding risk that warrants a blood pressure check before and after.

A 2018 review in Circulation examined PDE5 inhibitor safety in men with heart failure with preserved ejection fraction and found that tadalafil produced a statistically significant reduction in systemic vascular resistance (P<0.01) that was additive with background antihypertensive therapy [16]. Diphenhydramine's own vasodilatory contribution, though small, would add to this.

Men Using Alpha-Blockers for BPH

The tadalafil label specifically cautions about combining tadalafil with alpha-blockers such as tamsulosin, doxazosin, or alfuzosin because of additive hypotension [1]. Men on this combination who also take diphenhydramine face a three-drug hemodynamic interaction. A 2006 randomized crossover trial in the Journal of Urology (N=24) found that tadalafil 20 mg plus doxazosin 8 mg produced symptomatic hypotension in 4 of 24 subjects, with some subjects recording standing systolic pressures below 85 mmHg [17]. Adding diphenhydramine's anticholinergic and vasodilatory effects in this context is inadvisable without direct medical supervision.

Patient Counseling Points

Providers counseling patients about this combination should cover five areas:

Disclose all OTC use. Diphenhydramine is sold without a prescription in dozens of sleep aids (ZzzQuil, Unisom SleepTabs, Tylenol PM) and allergy products (Benadryl). Patients do not always connect OTC sleep aids with drug interactions. Ask specifically: "Do you take anything to help you sleep?"

Understand the urinary risk. Men taking tadalafil for BPH need to know that diphenhydramine works against tadalafil's urinary benefit. If voiding becomes slower or more difficult after taking an antihistamine or sleep aid, they should stop it and report to their provider.

Know the dizziness window. Tadalafil's 17.5-hour half-life means that dizziness and blood pressure effects persist well into the day after a bedtime dose [1]. A patient who takes tadalafil at 10 p.m. And diphenhydramine at midnight is still at risk for morning postural hypotension.

Prefer second-generation antihistamines. Loratadine, cetirizine, and fexofenadine offer comparable allergy relief with a substantially cleaner safety profile in this context [15].

Do not self-adjust tadalafil dose. Patients should not lower their tadalafil dose on their own to accommodate diphenhydramine use. Dose changes should be provider-directed based on indication (ED vs. BPH) and individual risk profile.

Men who use tadalafil 5 mg daily and need antihistamine coverage for seasonal allergies should ask their provider about switching to loratadine 10 mg daily as a standing alternative.